Indivior Pharmaceuticals (INDV) has announced the pricing of its offering of $450M in convertible senior notes due in 2031. The offering size was increased from an initial amount of $400M.

In March 2026, Indivior Pharmaceuticals, Inc. completed an upsized private offering of US$450,000,000 in 0.625% convertible senior unsecured notes due March 15, 2031, using the proceeds to repay ...

PAR Technology Corporation (NYSE: PAR) ("PAR" or the "Company") announced today its intention to offer $225.0 million ...

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due ...

BEIJING, March 13, 2026 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment ...

PAR Technology priced a $250M 4.00% convertible notes deal due 2031 to refinance 2027 notes and fund buybacks—see terms, proceeds and stock impact.

Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes. The stock was down 7.3% at $54.49 in Tuesday morning trading.

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2025) - First Majestic Silver Corp. (NYSE: AG) (TSX: AG) (FSE: FMV) ("First Majestic" or the "Company") announced today that it has priced ...

The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium The Company ...